MA26317A1 - Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation. - Google Patents

Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation.

Info

Publication number
MA26317A1
MA26317A1 MA27524A MA27524A MA26317A1 MA 26317 A1 MA26317 A1 MA 26317A1 MA 27524 A MA27524 A MA 27524A MA 27524 A MA27524 A MA 27524A MA 26317 A1 MA26317 A1 MA 26317A1
Authority
MA
Morocco
Prior art keywords
benzothiepine
active ingredients
dioxide derivatives
combined preparations
preparations
Prior art date
Application number
MA27524A
Other languages
English (en)
Inventor
Wendelin Frick
Heiner Glombik
Hans-Ludwig Schaefer
Werner Kramer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140169A external-priority patent/DE10140169A1/de
Priority claimed from DE10142456A external-priority patent/DE10142456A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MA26317A1 publication Critical patent/MA26317A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
MA27524A 2001-08-22 2004-02-11 Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation. MA26317A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10140169A DE10140169A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von 1,4-Benzothiepin-1,1-dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung
DE10142456A DE10142456A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von 1,4-Benzothiepin-1,1dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung

Publications (1)

Publication Number Publication Date
MA26317A1 true MA26317A1 (fr) 2004-10-01

Family

ID=26009944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27524A MA26317A1 (fr) 2001-08-22 2004-02-11 Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation.

Country Status (29)

Country Link
US (2) US20030158119A1 (fr)
EP (1) EP1425018B1 (fr)
JP (1) JP2005501861A (fr)
KR (1) KR20040032937A (fr)
CN (1) CN1655792A (fr)
AR (1) AR035285A1 (fr)
AT (1) ATE411802T1 (fr)
AU (1) AU2002333373B2 (fr)
BR (1) BR0212031A (fr)
CA (1) CA2457976A1 (fr)
CO (1) CO5560550A2 (fr)
DE (1) DE50212937D1 (fr)
HN (1) HN2002000235A (fr)
HR (1) HRP20040171A2 (fr)
HU (1) HUP0401318A3 (fr)
IL (1) IL160474A0 (fr)
MA (1) MA26317A1 (fr)
MX (1) MXPA04001328A (fr)
NO (1) NO20040702L (fr)
NZ (1) NZ531293A (fr)
OA (1) OA12654A (fr)
PA (1) PA8553201A1 (fr)
PE (1) PE20030361A1 (fr)
PL (1) PL366851A1 (fr)
RS (1) RS11104A (fr)
RU (1) RU2297222C2 (fr)
TN (1) TNSN04034A1 (fr)
UY (1) UY27419A1 (fr)
WO (1) WO2003018024A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
JP4711600B2 (ja) 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504878A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE102006053637B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP2010509252A (ja) 2006-11-14 2010-03-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
EP2367554A4 (fr) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
EP4137137A1 (fr) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Inhibiteurs et satiogènes de recyclage d'acide biliaire pour le traitement du diabète, de l'obésité et d'états gastro-intestinaux inflammatoires
EP2765855A4 (fr) 2011-10-12 2015-03-25 Merck Sharp & Dohme Compositions pharmaceutiques inhibant la dismutation
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CA2907230A1 (fr) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclerosante primaire et de la maladie inflammatoire de l'intestin
CA2907214A1 (fr) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire pour le traitement de l'ƒsophage de barrett et du reflux gastroƒsophagien pathologique
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
JP7562546B2 (ja) 2019-02-12 2024-10-07 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) * 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0876379A1 (fr) 1996-01-17 1998-11-11 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
PT1140187E (pt) * 1998-12-23 2004-01-30 Searle Llc Combinacoes de um inibidor de ibat e de um inibidor de mtp para indicacoes cardiovasculares
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
EP1175421A1 (fr) 1999-04-30 2002-01-30 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
DE60004066T2 (de) 1999-07-29 2004-04-15 Eli Lilly And Co., Indianapolis Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
DE50011035D1 (de) * 1999-09-01 2005-09-29 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2001083451A1 (fr) * 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Nouveaux composés bicycliques
CA2408486A1 (fr) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance
CA2410597A1 (fr) 2000-05-30 2001-12-06 Merck & Co., Inc. Agonistes du recepteur de la melanocortine
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use

Also Published As

Publication number Publication date
RU2004108119A (ru) 2005-04-10
BR0212031A (pt) 2004-08-03
CA2457976A1 (fr) 2003-03-06
NZ531293A (en) 2005-08-26
UY27419A1 (es) 2003-04-30
WO2003018024A1 (fr) 2003-03-06
CN1655792A (zh) 2005-08-17
AU2002333373B2 (en) 2006-12-14
TNSN04034A1 (en) 2006-06-01
IL160474A0 (en) 2004-07-25
RU2297222C2 (ru) 2007-04-20
US20030158119A1 (en) 2003-08-21
HRP20040171A2 (en) 2004-10-31
US20040097424A1 (en) 2004-05-20
NO20040702L (no) 2004-05-19
EP1425018B1 (fr) 2008-10-22
AR035285A1 (es) 2004-05-05
HUP0401318A3 (en) 2008-03-28
KR20040032937A (ko) 2004-04-17
ATE411802T1 (de) 2008-11-15
PA8553201A1 (es) 2004-08-31
HN2002000235A (es) 2003-02-18
PE20030361A1 (es) 2003-05-27
HUP0401318A2 (hu) 2004-10-28
OA12654A (en) 2006-06-15
PL366851A1 (en) 2005-02-07
JP2005501861A (ja) 2005-01-20
US7179792B2 (en) 2007-02-20
DE50212937D1 (de) 2008-12-04
EP1425018A1 (fr) 2004-06-09
MXPA04001328A (es) 2004-05-05
RS11104A (sr) 2006-12-15
CO5560550A2 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
MA26317A1 (fr) Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation.
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
ATE250924T1 (de) Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel
PT1242425E (pt) Compostos de n-(5,7-dimetoxi¬1,2,4|triazolo1,5-a|pirimidin-2-il) arilsulfonamida e sua utilizacao como herbicidas
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
EP1246792A4 (fr) Composes et compositions permettant d'administrer des principes actifs
NO20032187D0 (no) Heterocyklylalkylpiperidinderivater, deres fremstilling samt preparater inneholdende forbindelsene
EP1319402A4 (fr) INHIBITEURS DE PRODUCTION D'IgE
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
HUP0300653A3 (en) Liquid composition formulations, containing herbicidal active ingredients preparing and use thereof
TR200301931T2 (tr) Saç gelişiminde 3 konumundaki siklosporin türevlerinin kullanılması
NO20025277L (no) Farmasoytisk administreringsform for peptider, dens fremstilling samt anvendelse
FR2809730B1 (fr) Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
MXPA03001826A (es) Derivados de arilpiperazina.
EP1240902A4 (fr) Agents ameliorant le stress du au carbonyle
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
SE0001916D0 (sv) Novel formulation
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica